4737.TW
Bionime Corporation [4737.TW] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
4737.TW Stock Summary
Top 10 Correlated ETFs
4737.TW
Top 10 Correlated Stocks
4737.TW
In the News
4737.TW Financial details
Company Rating
Buy
Market Cap
4.25B
Income
6.77M
Revenue
1.76B
Book val./share
32.65
Cash/share
7.39
Dividend
2.1
Dividend %
2.88%
Employees
1.11K
Optionable
No
Shortable
Yes
Earnings
09 May 2024
P/E
188.55
Forward P/E
-
PEG
-20.29
P/S
2.3
P/B
2.22
P/C
9.5
P/FCF
-26.33
Quick Ratio
0.71
Current Ratio
1.12
Debt / Equity
1.42
LT Debt / Equity
0.85
-
-
EPS (TTM)
0.11
EPS next Y
-
EPS next Q
-
EPS this Y
-93.33%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-44.21%
Revenue last 5Y
-4.18%
Revenue Q/Q
15.17%
EPS Q/Q
-211.76%
-
-
-
-
SMA20
-1.41%
SMA50
-
SMA100
-11.39%
Inst Own
-
Inst Trans
-
ROA
-
ROE
1%
ROC
0.01%
Gross Margin
43%
Oper. Margin
2%
Profit Margin
1%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
67.2-90.1
52W High
-22%
52W Low
+4.78%
RSI
41
Rel Volume
0.46
Avg Volume
80.16K
Volume
37.05K
Perf Week
0.29%
Perf Month
-3.84%
Perf Quarter
-11.59%
Perf Half Y
-14.39%
-
-
-
-
Beta
0.59
-
-
Volatility
0.45%, 0.96%
Prev Close
1.74%
Price
70.2
Change
1.89%
4737.TW Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-12-31
| Metric | History | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 37.79 | 28.2 | 30.79 | 36.52 | 28.89 | |
| Net income per share | 1.85 | 1.06 | 1.45 | 1.5 | 0.1 | |
| Operating cash flow per share | 7.05 | 3.68 | 4.49 | 2.35 | 3.35 | |
| Free cash flow per share | 4.65 | -1.33 | -0.25 | -2.82 | -3.92 | |
| Cash per share | 6.64 | 6.75 | 5.21 | 4.59 | 7.39 | |
| Book value per share | 35.52 | 34.91 | 34.44 | 34.24 | 32.69 | |
| Tangible book value per share | 34.74 | 31.52 | 28.86 | 26 | 32.81 | |
| Share holders equity per share | 35.52 | 34.91 | 34.44 | 34.24 | 32.69 | |
| Interest debt per share | 32.64 | 34.28 | 34.13 | 38.01 | 47.16 | |
| Market cap | 4.63B | 4.02B | 4.55B | 4.67B | 4.54B | |
| Enterprise value | 6.11B | 5.68B | 6.33B | 6.73B | 6.97B | |
| P/E ratio | 43.56 | 64.36 | 52.1 | 51.34 | 731.94 | |
| Price to sales ratio | 2.13 | 2.41 | 2.46 | 2.11 | 2.59 | |
| POCF ratio | 11.41 | 18.47 | 16.88 | 32.84 | 22.34 | |
| PFCF ratio | 17.3 | -50.97 | -306.72 | -27.39 | -19.1 | |
| P/B Ratio | 2.27 | 1.95 | 2.2 | 2.25 | 2.29 | |
| PTB ratio | 2.27 | 1.95 | 2.2 | 2.25 | 2.29 | |
| EV to sales | 2.81 | 3.41 | 3.42 | 3.04 | 3.97 | |
| Enterprise value over EBITDA | 17.93 | 23.73 | 27.81 | 22.43 | 48.65 | |
| EV to operating cash flow | 15.08 | 26.12 | 23.48 | 47.29 | 34.26 | |
| EV to free cash flow | 22.86 | -72.07 | -426.51 | -39.44 | -29.29 | |
| Earnings yield | 0.02 | 0.02 | 0.02 | 0.02 | 0 | |
| Free cash flow yield | 0.06 | -0.02 | 0 | -0.04 | -0.05 | |
| Debt to equity | 0.9 | 0.97 | 0.98 | 1.1 | 1.42 | |
| Debt to assets | 0.42 | 0.45 | 0.45 | 0.46 | 0.53 | |
| Net debt to EBITDA | 4.36 | 6.95 | 7.81 | 6.85 | 16.93 | |
| Current ratio | 1.16 | 1.17 | 1.05 | 1.16 | 1.01 | |
| Interest coverage | 5.55 | 3.52 | 3.84 | 4.79 | -0.28 | |
| Income quality | 3.01 | 6.99 | 3.62 | 1.65 | -6.38 | |
| Dividend Yield | 0.02 | 0.03 | 0.03 | 0.03 | 0.03 | |
| Payout ratio | 1.08 | 1.9 | 1.42 | 1.33 | 20.56 | |
| Sales general and administrative to revenue | 0.12 | 0.13 | 0.13 | 0.11 | 0.14 | |
| Research and developement to revenue | 0.12 | 0.15 | 0.1 | 0.09 | 0.14 | |
| Intangibles to total assets | 0.01 | 0.05 | 0.07 | 0.1 | 0.12 | |
| Capex to operating cash flow | -0.34 | -1.36 | -1.06 | -2.2 | -2.17 | |
| Capex to revenue | -0.06 | -0.18 | -0.15 | -0.14 | -0.25 | |
| Capex to depreciation | -0.84 | -1.81 | -1.84 | -2.04 | -2.7 | |
| Stock based compensation to revenue | 0.01 | 0.01 | 0.01 | 0 | 0 | |
| Graham number | 38.43 | 28.79 | 33.58 | 34.03 | 8.67 | |
| ROIC | 0.04 | 0.04 | 0.02 | 0.04 | 0 | |
| Return on tangible assets | 0.02 | 0.01 | 0.02 | 0.02 | 0 | |
| Graham Net | -20.44 | -23.03 | -25.44 | -28.97 | -34.98 | |
| Working capital | 214.47M | 216.26M | 60.29M | 225.66M | 8.24M | |
| Tangible asset value | 2B | 1.87B | 1.73B | 1.57B | 1.35B | |
| Net current asset value | -761.96M | -956.96M | -1.1B | -1.27B | -1.69B | |
| Invested capital | 0.9 | 0.97 | 0.98 | 1.1 | 1.42 | |
| Average receivables | 835.02M | 663.08M | 495.75M | 635.68M | 726.25M | |
| Average payables | 155.93M | 147.68M | 148.72M | 165.16M | 163.44M | |
| Average inventory | 403.93M | 457.76M | 555.12M | 564.29M | 514.85M | |
| Days sales outstanding | 134.94 | 114.37 | 92.47 | 132.54 | 135.1 | |
| Days payables outstanding | 44.42 | 58.08 | 51.71 | 54.21 | 51.84 | |
| Days of inventory on hand | 117.87 | 206.46 | 201.92 | 162.9 | 172.43 | |
| Receivables turnover | 2.7 | 3.19 | 3.95 | 2.75 | 2.7 | |
| Payables turnover | 8.22 | 6.28 | 7.06 | 6.73 | 7.04 | |
| Inventory turnover | 3.1 | 1.77 | 1.81 | 2.24 | 2.12 | |
| ROE | 0.05 | 0.03 | 0.04 | 0.04 | 0 | |
| Capex per share | -2.4 | -5.01 | -4.74 | -5.17 | -7.26 |
Quarterly Fundamentals Overview
Last date of statement is 2023-12-31 for Q4
| Metric | History | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 9.84 | 6.84 | 7.01 | 6.99 | 8.05 | |
| Net income per share | 0.46 | -0.08 | 0.17 | -0.17 | 0.19 | |
| Operating cash flow per share | 1.97 | 2.85 | -0.89 | 0.97 | 0.43 | |
| Free cash flow per share | -0.13 | 0.78 | -2.04 | -1.29 | -1.37 | |
| Cash per share | 4.58 | 5.54 | 5.55 | 6.15 | 7.39 | |
| Book value per share | 34.18 | 32 | 32.17 | 32.13 | 32.65 | |
| Tangible book value per share | 25.96 | 23.08 | 22.73 | 32.25 | 32.77 | |
| Share holders equity per share | 34.18 | 32 | 32.17 | 32.13 | 32.65 | |
| Interest debt per share | 37.6 | 38.01 | 40.1 | 43.94 | 46.56 | |
| Market cap | 4.68B | 4.65B | 4.7B | 4.47B | 4.55B | |
| Enterprise value | 6.74B | 6.68B | 6.85B | 6.82B | 6.97B | |
| P/E ratio | 42.26 | -228.28 | 111.63 | -110.58 | 99.32 | |
| Price to sales ratio | 7.84 | 11.2 | 11.04 | 10.53 | 9.29 | |
| POCF ratio | 39.25 | 26.9 | -86.54 | 75.85 | 175.27 | |
| PFCF ratio | -588.8 | 97.69 | -38.02 | -56.89 | -54.64 | |
| P/B Ratio | 2.26 | 2.39 | 2.41 | 2.29 | 2.29 | |
| PTB ratio | 2.26 | 2.39 | 2.41 | 2.29 | 2.29 | |
| EV to sales | 11.29 | 16.08 | 16.1 | 16.04 | 14.24 | |
| Enterprise value over EBITDA | 86.61 | 221.82 | 149.58 | 172.86 | 249.83 | |
| EV to operating cash flow | 56.48 | 38.64 | -126.13 | 115.59 | 268.71 | |
| EV to free cash flow | -847.42 | 140.31 | -55.42 | -86.69 | -83.77 | |
| Earnings yield | 0.01 | 0 | 0 | 0 | 0 | |
| Free cash flow yield | 0 | 0.01 | -0.03 | -0.02 | -0.02 | |
| Debt to equity | 1.1 | 1.18 | 1.24 | 1.36 | 1.42 | |
| Debt to assets | 0.46 | 0.46 | 0.48 | 0.52 | 0.53 | |
| Net debt to EBITDA | 26.43 | 67.38 | 46.96 | 59.42 | 86.87 | |
| Current ratio | 1.16 | 0.93 | 0.92 | 1.12 | 1.01 | |
| Interest coverage | 4.02 | -0.91 | 0.4 | -0.21 | -1.46 | |
| Income quality | 5.55 | -11.1 | -2.35 | -4.52 | -0.98 | |
| Dividend Yield | 0 | 0 | 0 | 0.03 | 0 | |
| Payout ratio | 0 | 0 | 0 | -12.62 | 0 | |
| Sales general and administrative to revenue | 0.12 | 0.14 | 0.13 | 0.15 | 0.13 | |
| Research and developement to revenue | 0.1 | 0.12 | 0.11 | 0.14 | 0.18 | |
| Intangibles to total assets | 0.1 | 0.11 | 0.12 | 0.12 | 0.12 | |
| Capex to operating cash flow | -1.07 | -0.72 | 1.28 | -2.33 | -4.21 | |
| Capex to revenue | -0.21 | -0.3 | -0.16 | -0.32 | -0.22 | |
| Capex to depreciation | -3.26 | -3.21 | -1.68 | -3.27 | -2.65 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 18.74 | 7.77 | 11.2 | 10.97 | 11.76 | |
| ROIC | 0.01 | 0 | 0 | 0 | 0 | |
| Return on tangible assets | 0.01 | 0 | 0 | 0 | 0 | |
| Graham Net | -28.92 | -32.41 | -32.57 | -33.6 | -34.94 | |
| Working capital | 225.66M | -119.98M | -139.91M | 158.64M | 8.24M | |
| Tangible asset value | 1.57B | 1.4B | 1.38B | 1.33B | 1.35B | |
| Net current asset value | -1.27B | -1.51B | -1.52B | -1.61B | -1.69B | |
| Invested capital | 1.1 | 1.18 | 1.24 | 1.36 | 1.42 | |
| Average receivables | 782.91M | 667.71M | 562.72M | 589.32M | 617.86M | |
| Average payables | 182.83M | 177.28M | 154.21M | 128.87M | 136.18M | |
| Average inventory | 545.58M | 564.01M | 580.75M | 549.98M | 509.65M | |
| Days sales outstanding | 121.06 | 115.49 | 125.33 | 124.03 | 119.43 | |
| Days payables outstanding | 55.04 | 65.15 | 47.11 | 42.39 | 47.68 | |
| Days of inventory on hand | 165.39 | 219.05 | 202.48 | 179.54 | 158.6 | |
| Receivables turnover | 0.74 | 0.78 | 0.72 | 0.73 | 0.75 | |
| Payables turnover | 1.64 | 1.38 | 1.91 | 2.12 | 1.89 | |
| Inventory turnover | 0.54 | 0.41 | 0.44 | 0.5 | 0.57 | |
| ROE | 0.01 | 0 | 0.01 | -0.01 | 0.01 | |
| Capex per share | -2.1 | -2.06 | -1.14 | -2.26 | -1.8 |
4737.TW Frequently Asked Questions
What is Bionime Corporation stock symbol ?
Bionime Corporation is a TW stock and trading under the symbol 4737.TW
What is Bionime Corporation stock quote today ?
Bionime Corporation stock price is $70.2 today.
Is Bionime Corporation stock public?
Yes, Bionime Corporation is a publicly traded company.
Company Profile
- Volume Average 80.16K
- Market Capitalization 4.25B
- Employee 1.11K
- CEO Mr. Chun-Mu Huang
- Headquarters Taichung,TW
- IPO Date 2010-12-23
-
Website
https://www.bionime.com 
Bionime Corporation designs, manufactures, and sells medical instruments in China, Switzerland, the United States, Algeria, Egypt, and internationally. The company offers blood glucose monitors, as well as accessories, such as test strips and lancing devices medical equipment companies, pharmacies, and hospitals. It is also involved in the provision of biotechnology services; examining of pharmaceuticals; and selling of precision instruments. The company was incorporated in 2003 and is based in Taichung, Taiwan.
